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Mutational Landscape of Basal Cell Carcinomas by
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Shyam S. Jayaraman1, David J. Rayhan2, Salar Hazany2 and Michael S. Kolodney1
Recent advances in sequencing technology allow genome-scale approaches to cancer mutation discovery. Such
data-intensive methods have been applied to cutaneous squamous cell carcinomas (SCCs) and melanomas but
have not, to our knowledge, been applied to basal cell carcinomas (BCCs). We used whole-exome sequencing to
characterize the mutational landscape of sporadic BCCs. We show that BCCs are the most mutated type of
human cancer. Tumors from anatomical regions with chronic UV exposure were associated with higher mutation
rates than those with intermittent exposure. The majority of all mutations (75.7%) were UV signature. Using a
conventional binomial probability model, several genes were found mutated significantly. However, this model
assumes a uniform distribution of mutations throughout the genome. We also used a more stringent approach
called InVEx that uses a permutation-based framework to pick drivers from passengers. After correction for
multiple hypothesis testing, InVEx identified only PTCH1 (Patched 1) as having a significant functional mutation
burden. We also found three genes, STAT5B, CRNKL1, and NEBL, with mutational hot spots at a single base in 3 of
12 tumors sequenced. Our findings support the central role of PTCH1 mutations in BCCgenesis. Moreover, our
discovery of the uniquely high number of mutations in this tumor may lend insight into its biological behavior.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common human
cancer, accounting for 80–90% of all primary skin cancers
(Scotto et al., 1983; Iwasaki et al., 2012). UV exposure is the
most important risk factor in basal cell carcinogenesis. However,
crucial insight into the biology of BCC came from linkage
analysis of families with a rare inherited form of the disease.
Studies on Gorlin’s syndrome, an autosomal dominant
disorder predisposing to multiple BCCs, initially demonstrated
a pivotal role for the sonic hedgehog (SHH) pathway in BCC.
Pioneering linkage analysis of families with this syndrome
localized a putative tumor-suppressor gene to 9q22.3–q31
(Farndon et al., 1992; Gailani et al., 1992; Reis et al., 1992).
Further studies (Chenevix-Trench et al., 1993; Shanley et al.,
1995) led to the identification of mutations in the human
homolog of the Drosophila patched protein as the cause of
Gorlin’s syndrome (Hahn et al., 1996; Johnson et al., 1996).
Further research has confirmed the central role of the SHH/
PTCH1/SMO pathway in sporadic BCCs. PTCH1 (Patched 1)
normally acts to keep the activity of SMO (Smoothened) in
check, by playing an inhibitory role. The binding of SHH to
the extracellular domain of PTCH1 relieves SMO inhibition,
leading to activation of the GLI transcription factors that
regulate the transcription of hedgehog target genes.
Recently, the Patched pathway became a therapeutic target
with the introduction of a clinically effective small-molecule
antagonist of the SMO receptor—Vismodegib (Rudin, 2012).
Numerous studies of sporadic BCCs have reported point
mutations, copy-loss loss of heterozygosity (LoH), and copy-
neutral LoH (due to uniparental disomy) in PTCH1 (Teh et al.,
2005; Santos et al., 2011). For example, one study (Teh et al.,
2005) reported a highly conserved LoH region at 9q21–q31
found in 13 of 14 (93%) BCCs with uniparental disomy being
found in 5 of 13 (38%) BCCs. The de novo mutations in the
PTCH1 gene were found in 9 of 13 (69%) BCCs with 9q LoH.
Point mutations of both the substitution missense and sub-
stitution nonsense types have been described throughout the
length of the PTCH1 protein.
The second important gene in BCCgenesis is TP53 (Shea
et al., 1992; Ziegler et al., 1993). TP53 codes for the P53
protein that maintains genomic stability by regulating the cell
cycle, activating DNA repair, and inducing apoptosis. TP53 is
mutated in anywhere from 30 to 70% of basal cell tumors
(Lacour, 2002; Reifenberger et al., 2005; Tang, 2011). Thus,
mutations in both the SHH/Patched/SMO pathway and TP53
have long been known to play a major role in basal cell
carcinogenesis, the former in both the inherited (Gorlin’s
syndrome) and sporadic forms of the disease.
In contrast to the aforementioned directed approaches
that identified the cancer genes PTCH1 and TP53, recent
advances in sequencing technology have permitted unbiased
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approaches to the discovery of cancer mutations. Directed
approaches characterize the prevalence of mutations in
known oncogenic genes in a cancer of interest. Unbiased
approaches sequence a substantial portion of the tumor’s
genome rather than specific genes of particular interest. These
tumor genetic sequences are compared with sequences from
normal cells, of the same individual, to identify cancer-
specific mutations. One such unbiased approach is whole-
exome sequencing. In this method, the genome is enriched for
exons—that portion of the genomic code that exits the nucleus
for participation in protein translation. Because such studies
examine the entire set of protein coding human genes, these
approaches have a greater power to detect novel genes
involved in tumorigenesis compared with those that target
only a small subset of the human exome. Application of this
unbiased approach has identified novel mutations in most
common cancers including cutaneous squamous cell carci-
noma (SCC) and cutaneous malignant melanoma (Durinck
et al., 2011; Wei et al., 2011; Berger et al., 2012; Hodis et al.,
2012). However, to our knowledge, a similar effort has not
been put into the study of BCCs that are more prevalent than
other cutaneous malignancies. We have applied whole-exome
sequencing to sporadic BCCs in an attempt to better
understand the mutational landscape of the single most
common cancer worldwide.
RESULTS
Detection of mutations in protein coding DNA
We performed whole-exome sequencing on paired tumor and
normal DNA specimens obtained from 12 tumors (10 patients)
with histologically confirmed BCC. In both tumor and normal,
65-fold mean coverage was achieved with 89.2% of bases on
average covered at least 15-fold.
A total of 27,286 mutations were uncovered in the ‘‘protein
coding’’ DNA regions spanning B30 million base pairs per
human genome (Ng et al., 2009) (to be contrasted with
‘‘exonic’’ regions; nearly half of all ‘‘exonic’’ regions are not
‘‘protein coding’’ because the human genome has massive
lengths of 50 and 30 untranslated regions) across all samples,
giving a rate of 75.8 mutations per Mb of coding DNA. This
figure is the highest reported in any type of human cancer
(those arising in patients with nucleotide excision repair
defects may be a possible exception) and more than twice
as much as the previously reported high with cutaneous SCC,
which is a distant second at 33.3 per Mb of coding DNA
(Durinck et al., 2011). Several other types of human cancers
have been shown to have mutation rates that are much lower
than these. The interested reader is referred to Table 1 in
Greenman et al. (2007) who use direct PCR sequencing of a
subset of the protein coding regions to calculate mutation rates
on multiple tumor types. As expected, a majority of point
Table 1. UV signature mutation spectrum in all samples
Mutation type
C4T transitions at dipyrimidinic sites across all
samples (YC:RG4YT: RA) except tandem base
substitutions (CC:GG4TT:AA)
Tandem base substitutions at CC sites
across all samples (CC:GG4TT:AA),
each counted as 2
Total ‘‘UV Signature’’
(Ikehata and Ono, 2011)
Number 18,212 2,440 20,652
Mean proportion of
coding mutations
66.7% 8.9% 75.7%
G4T (oxidative) and T4G (UVA fingerprint) are not included here because of their uncertain UV origins.
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Figure 1. (a) Number of coding mutations versus age and photo exposure;
each data point represents one tumor. There is a slight trend (blue line) of
increasing mutation rates with age in tumors from ‘‘protected’’ (intermittently
sun-exposed) parts. Mutations rates are higher in chronically sun-exposed
versus intermittently sun-exposed parts (yellow vs. red data points). (b) Q-Q
plot of functional mutation burden test and synonymous mutation burden test
across all genes with at least 1 mutation in the set of 12 tumors. Gray-shaded
area represents 95% confidence intervals for expected P-values. Red points:
functional mutation burden; yellow points: synonymous mutation burden.
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mutations in BCCs were UV induced, particularly the ‘‘UV
Signature’’ (Ikehata and Ono, 2011) mutations (Table 1). The
ratio of single-nucleotide transitions to tandem base transitions
(CC4TT) was found to be 7.5:1.
A total of 8,543 genes contained a nonsilent mutation in at
least one tumor, 3,553 were mutated in two or more tumors,
and 165 genes were mutated in at least half (six) of the
tumors. The latter included known/putative cancer genes
such as CSMD1 (11 of 12) (Richter et al., 2005; Tang et al.,
2012) and homologs CSMD2 (8 of 12), CSMD3 (7 of 12) ),
DCC (6 of 12), DPP10 (9 of 12) (Bueno et al., 2010),
GRIN2A (6 of 12) (Wei et al., 2011), NOTCH1 (6 of 12)
(Agrawal et al., 2011; Durinck et al., 2011; Wang et al.,
2011), and homolog NOTCH2 (8 of 12) ) and PREX2 (7
of 12) (Berger et al., 2012). CSMD1, GRIN2A, NOTCH1 and
PREX2, as referenced, have been implicated in nonbasal cell
cutaneous malignancy.
Figure 1a shows a trend toward more mutations with
increasing age in tumors from intermittently sun-exposed parts
of the body, whereas no such trend is discerned in those from
chronically sun-exposed parts (face, scalp, lateral and posterior
forearms, and upper chest) presumably because the variability
in the amount of exposure obliterates any underlying age-
related trend. However, it is noteworthy that tumors from
chronically sun-exposed parts of the body are markedly more
mutated than those that are not.
Aneuploidy
Aneuploidy (an abnormality in the number of chromosomes,
the number not being a multiple of the haploid set) was
fairly common. Copy loss/gain regions spanning whole
chromosomes were seen in over half (7 of 12) of all
tumors. Recurrent events included loss-chr13 in two tumors
and gain-chr20 in two tumors, besides gain-chr6, loss-chr9,
loss-chr14, loss-chrX, and gain-chrY, which were found in one
tumor each.
PTCH1 and TP53
PTCH1 and TP53 were mutated in 9 (75%) and 8 tumors
(66%), respectively. PTCH1 exhibited an interesting spectrum
of nonsynonymous mutations with a predominance of non-
sense and splice site mutations (Figure 2 and Table 2a). In
addition, a frameshift deletion and two missense mutations,
one of which was scored ‘‘deleterious’’ by the Polyphen2
functional prediction scoring system, were found. Thus, there
was a complete/partial loss of function of one copy of the
PTCH1 gene in 9 of 12 tumors, from point mutations.
Moreover, LoH of PTCH1 ascribable to segmental aneu-
ploidy (allelic loss LoH) was found in 5 of 12 tumors
evidenced by a copy loss in the chr9q region encompassing
the PTCH1 locus,chr9q22; 1 of the 5 was a complete loss of
chr9 (Figure 3).
In contrast to PTCH1, the mutations in TP53 were pre-
dominantly missense mutations (Table 2b). All of these
missense mutations were scored ‘‘deleterious’’ by Polyphen2
(an algorithm that predicts possible impact of an amino acid
substitution on the structure and function of a human protein
using straightforward physical and comparative considera-
tions). All of the amino acid positions that were mutated were
reported previously mutated in COSMIC (Forbes et al., 2008).
Interestingly, unlike the PTCH1 locus, there were no copy
losses identified at the TP53 locus.
Drivers versus passengers
Picking driver mutations (i.e., mutations that confer or at some
point conferred a fitness advantage to the tumor cell) from the
multitude of mutations found in a tumor is a rapidly evolving
area of research. High somatic mutation rates (such as we
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Figure 2. Schematic of Patched 1 (PTCH1) protein with mutations observed (cf. Table 2). Red octagons/stop signs: protein truncations; yellow squares:
amino acid substitutions; yellow asterisk: frameshift; green scissors: splice site mutations. ECL, extracellular loop; ICL, intracellular loop; TM, transmembrane
domain.
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have shown with BCCs) that vary across genomic loci may
limit the statistical validity of approaches assuming uniformity
of the background mutation rate (Hodis et al., 2012). A
method that accounts for the confounding effects of
regionally variable basal mutation rates (besides other
factors) was wanting. Hence, we sought recourse to a novel
algorithm called InVEx, an algorithm that compares mutation
rates in Introns versus Exons, developed at the Broad Institute
(see Materials and Methods section for description).
After correction of P-values for multiple hypothesis testing,
InVEx generated the Q-Q plot shown in Figure 1b. This graph
shows expected versus observed P-values with those genes
whose Q-values (adjusted P-values) are less than the cutoff
being labeled explicitly, for our data. Several genes had
significantly low P-values (including TP53, which was ranked
20), before multiple hypothesis testing correction was carried
out. When corrected for the large number of hypotheses
tested, only one (PTCH1; labeled in graph) of the 8,543
nonsilently mutated genes had a statistically significant func-
tional mutation burden by this approach.
More genes were found significantly mutated when using a
simple binomial probability distribution accounting for protein
(and hence coding region) size (refer Materials and Methods).
The top genes and their corresponding P-values are given in
Table 3. Known/putative cancer genes among these include
TP53, PTCH1, DPP10, ITIH2 (Hamm et al., 2008), and
STEAP4 (Grunewald et al., 2012).
Hot spot mutations
Three genes were mutated at the same amino acid in
three tumors each. They are STAT5B (P736L in 2 tumors
and P736F in 1 tumor), CRNKL1 (S128F), and NEBL
(D803N); mutations at these loci have not been previously
documented in the cancer mutation database, COSMIC,
or in dbSNP. At the nucleotide level, all of them were due
to C4T transitions.
Table 2. Mutation spectrum in (a) PTCH1 and (b) TP53 genes
PTCH1
Sample ID Chr Coordinate Variant classification Reference allele Tumor allele Protein change
Sample 5 9 98,212,223 Splice site C T p.R1150_splice
Sample 2 9 98,218,697 Splice site T C p.V1057_splice
Sample 11 9 98,229,401 Nonsense mutation G A p.Q853*
Sample 11 9 98,231,313 Frameshift deletion GTAATCTGCGTT G p.E653fs
Sample 11 9 98,238,318 Nonsense mutation G A p.Q576*
Sample 6 9 98,238,442 Splice site C T p.D535_splice
Sample 9 9 98,241,336 Nonsense mutation C T p.W387*
Sample 1 9 98,241,404 Nonsense mutation G A p.Q365*
Sample 10 9 98,244,268 Missense mutation C T p.E237K
Sample 10 9 98,244,269 Nonsense mutation C T p.W236*
Sample 3 9 98,248,001 Nonsense mutation G A p.Q184*
Sample 1 9 98,248,100 Missense mutation C T p.A151T
Sample 7 9 98,268,833 Nonsense mutation G A p.Q84*
TP53
Sample 2 17 7,574,003 Nonsense mutation G A p.R342*
Sample 1 17 7,577,074 Frameshift deletion AT A p.N288fs
Sample 12 17 7,577,108 Missense mutation C A p.C277F
Sample 2 17 7,577,141 Missense mutation C T p.G266E
Sample 1 17 7,577,509 Missense mutation C T p.E258K
Sample 3 17 7,577,539 Missense mutation G A p.R248W
Sample 4 17 7,577,539 Missense mutation G A p.R248W
Sample 11 17 7,578,401 Missense mutation G A p.P177S
Sample 12 17 7,578,401 Missense mutation G A p.P177S
Sample 8 17 7,578,476 Missense mutation G A p.P152S
Sample 6 17 7,579,311 Splice site C T p.T125_splice
In ‘a’: box indicates tandem substitution.
In ‘b’: box indicates hot spots; previously reported in COSMIC in other cancers. Also found to increase basal cell carcinoma risk (Ouhtit et al., 1998).
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STAT5B performs a dual function of signal transduction and
activation of transcription and has been definitively implicated
in pancreatic, breast, myeloproliferative disorders, and other
tumors. CRNKL1 is involved in the pre-mRNA splicing process
and loss of function would presumably lead to splicing
defects. STAT5B and CRNKL1 are widely expressed; the
nonmuscle isoform of NEBL, Isoform 2, is also widely
expressed, including in fibroblasts and may play a role in
focal adhesion. The latter two genes have been found mutated
at other loci in a variety of cancers, as documented in
COSMIC, but not as consistently as described here.
Recurrent copy number aberrations
Copy number aberrations involving the PTCH1 locus and
aneuploidies have been presented above. In addition, copy
number aberrations involving regions of chr4q and chr8q
were found in 3 tumors (25%) each. The overlap in each
set of 3 localized to a copy loss at 4q31.3–4q35.1 and a copy
gain at 8q23.3–8q24.3. Potential cancer genes may reside in
these loci.
DISCUSSION
Bioinformatics is a rapidly evolving branch of genome science
and there are no gold standards for constructing an analysis
pipeline—every researcher ‘‘spins their own’’ and some tools
are widely accepted at a point in time only to be replaced by
more robust methods, sooner than later. There are two
possible variables in a bioinformatics pipeline that can affect
estimates of mutation rates in exome sequencing experiments:
the aligner used to align reads to a reference genome and the
mutation caller/parameters used to call out single-nucleotide
variants. The former has been shown to have only minimal
negligible effects on mutation rates, at least among the popular
short read aligners (http://massgenomics.org/2009/07/maq-
bwa-and-bowtie-compared.html). The effects of the latter, on
the contrary, are potentially more, given the plethora of
mutation callers available that can be used on exome data,
each using a different algorithm. We have resorted to using a
mutation caller with a robust algorithm and that is widely
accepted at this point in time.
We have used whole-exome sequencing to characterize the
genetic landscape of sporadic BCCs. Our results demonstrate
that BCCs carry a greater mutational burden than any known
human cancer. Whether this explains the behavior of the
tumor in terms of the very slow growth rate and very rare
metastases (o0.003 to 0.5%; Weiss and Korn, 2012) will be
an interesting question to answer on the biology of human
cancer in general. We hypothesize that, with more mutated
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Figure 3. Chr9 copy number data. Yellow-brown regions are regions of normal copy number. Green regions are regions of copy number loss. The Patched 1
(PTCH1) locus on chr9q22 is marked with red boxes on the banding maps at the bottom (blue arrow). Normal copy number profile from one sample (7) is provided
for comparison; 8 is monosomic for chr9. This figure was generated using CEQer.
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proteins, the hosts’ immune systems mount a more
effective antitumor response, leading to a less aggressive
phenotype. Although this hypothesis will require further
investigation, we find it interesting that BCCs and SCCs are
two of the tumors most increased by immunosuppression.
Absence of any copy loss at the TP53 locus is noteworthy
as TP53 usually functions as a tumor-suppressor gene
requiring biallelic inactivation. This is similar to the
findings in a previous study, where BCCs were found to
have only one copy of the TP53 allele inactivated (Van der
Riet et al., 1994), the other copy of the gene being
entirely intact. If and how TP53 contributes to BCCgenesis
in this scenario is unexplained. Our study did not reveal any
copy-neutral LoH in PTCH1 or TP53; whether uniparental
disomy (Teh et al., 2005; Tuna et al., 2009) causes
copy-neutral LoH of PTCH1 (in those tumors without
copy-loss LoH) and of TP53 is a question that is best
addressed with a high-resolution single-nucleotide polymor-
phism microarray.
Our study reaffirms the central role of PTCH1 in BCCgen-
esis. It was the only gene to reach functional statistical
significance with InVEx due to a plethora of loss-of-function
mutations. With such a high total mutation rate, it is highly
improbable that BCCs are so homogenous in their genetic
origins that only one pathway is contributory. Even though
genes like CSMD1, CSMD2, NOTCH1, NOTCH2, GRIN2A,
and PREX2 were found to be frequently mutated in our study
as in SCCs and melanomas, our study did not conclusively
identify any novel genes as drivers in BCC. The relatively
small sample size and high mutation rate limits the statistical
power to detect significantly mutated genes using an algorithm
as rigorous as InVEx. Larger-scale studies using the same
algorithm may be of a more revealing nature.
MATERIALS AND METHODS
Clinical samples
All BCC samples and peripheral blood collected and sequenced in
this study were done under protocols approved by the Institutional
Review Board of Los Angeles Biomedical Research Institute.
‘‘Declaration of Helsinki’’ Principles were followed and patients gave
their written informed consent before enrollment and sample collec-
tion. Only tumors with 480% tumor area on histological section
were chosen for exome sequencing. DNA was extracted using the
Roche MagnaPure automated system (Switzerland).
Sequencing
Seqcap EZ Human Exome Library 2.0 from Roche Nimblegen was
used for exome capture and sequenced on IlluminaHiSeq 2000
machines (San Diego, CA), generating 2 100 bp paired end reads.
Prevariant processing pipeline
Paired end reads were gap aligned to hg19 using BWA (Burrows–
Wheeler Aligner). Poorly aligned/mapped reads were filtered
away with Samtools; SAM to BAM conversion was done. PCR
duplicates were marked and removed with the Picard package. Indel
realignment with known sites and base quality score recalibration
were performed with GATK (Genome Analysis Toolkit), in line with
current best practices in the next-generation sequencing field for
variant detection, to produce variant-caller ready reads in BAM
format.
Variant calling: identification of somatic substitutions and short
indels
Somatic single-nucleotide variants were called with MuTect
(beta) (https://confluence.broadinstitute.org/display/CGATools/MuTect).
Single-nucleotide variants reported in dbSNP129 (the last accepted
‘‘pure’’ version of dbSNP) were removed, unless they were also
present in COSMICv56 (Forbes et al., 2008). Somatic short indels
were called with the Somatic Indel Detector walker that is part
of the GATK package (https://confluence.broadinstitute.org/display/
CGATools/Indelocator). Both these programs take in paired tumor-
normal BAMs as input. The single-nucleotide variants and indels were
annotated with Oncotator (http://www.broadinstitute.org/oncotator/),
a rapid and accurate web-based annotation tool.
Passengers versus drivers
We employed two methods to address this question:
1. InVEx (for ‘‘Introns vs. Exons’’) was used; it is available at
http://www.broadinstitute.org/software/invex/. Its use was first
reported by Hodis et al (2012) and, in essence, it statistically
assesses, through a permutation-based framework, positive
selection for nonsynonymous mutations in a gene by comparing
the number of such mutations with synonymous mutations and
mutations in flanking intronic and 50/30 untranslated regions.
Table 3. Significantly mutated genes using a simple
binomial probability distribution
Gene name Number of samples with hits P-value
TP53 8 4.24591E 08
DPP10 9 4.17483E 07
C7 9 6.64305E 07
OR5M3 6 5.56997E 06
UGT2B10 7 7.51978E 06
GPR139 6 1.21057E 05
PCDHGB3 8 2.19845E 05
ITIH2 8 2.49134E 05
TMEM217 5 2.63321E 05
PTCH1 9 4.42967E 05
STEAP4 6 5.07893E 05
TMEM132D 8 6.90538E 05
PPP1R3A 8 7.93271E 05
KCNT2 8 8.5668E 05
POM121L12 5 8.64377E 05
HEATR7B2 9 8.65047E 05
PCDHB3 7 9.50472E 05
DPCR1 6 9.59935E 05
PCDHB2 7 9.64891E 05
NPAP1 8 9.67858E 05
SULT1C3 5 9.76587E 05
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A gene that harbors a high frequency of nonsynonymous muta-
tions and a low frequency of synonymous/intronic/untranslated
region mutations presumably is positively selected during tumor
evolution. If the difference in these frequencies is statistically
significant, the gene and its protein product will be reported as
drivers in tumorigenesis.
Nucleotides were mutated randomly across the gene’s covered
base pairs, respecting trinucleotide context, and the mutation
burden score of each randomized instance was calculated. Up to
108 such permutations were generated and scored for each gene.
The fraction of mutation burden scores for random instances that
was equal to or greater than the observed burden defined the
P-value.
The driver genes so obtained are more likely biologically meaning-
ful than previous approaches that have been used in the field of
bioinformatics.
2. A simple binomial probability distribution was used.
N¼ number of tumors, e.g., 12;
k¼ number of tumors nonsynonymously mutated in the gene of
interest, e.g., 7;
p¼ probability of at least one nonsilent mutation in the gene
of interest in a tumor (1—probability of zero nonsilent muta-
tions; where probability of zero non-silent mutations is calcu-
lated as probability of a base being NOT mutated nonsilently raised
to the power of total number of coding bases in that gene)
q¼ (1 p)
Pðk out of NÞ¼ ðN ! =ðk ! ðNkÞ ! ÞÞðpkÞðqðNk ÞÞ
The resulting P-values were sorted in ascending order.
Copy number and allelic imbalance
CEQer, for ‘‘Comparative Exome Quantification Analyser,’’ devel-
oped by Rocco Piazza at the University of Milano-Bicocca, was used
for exome copy number and LoH analysis (used in Piazza et al.,
2012).
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